Fusion Pharmaceuticals Appoints New Chief Medical Officer

23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James J. O’Leary, M.D., as chief medical officer (CMO).

“With his extensive experience and skills as a medical oncologist and drug developer in the precision oncology space, Jim will make an immediate contribution to Fusion’s clinical strategy and lead the growth of our clinical team and programs,” said John Valliant, chief executive officer. “Fusion is building a diverse pipeline of innovative radiopharmaceutical cancer therapy candidates through our platform technology, and Jim’s ability to evaluate assets and tailor clinical studies will be invaluable as we execute our corporate plan.  In addition, his background as a medical oncologist provides him with valuable insights and a focus on advancing innovative cancer therapies for patients.”

Dr. O’Leary brings to Fusion more than 20 years of oncology industry experience including roles within biotechnology companies such as ImmunoGen, Idera Pharmaceuticals, Array Biopharma, and Deciphera, and pharmaceutical companies including Takeda, Bayer and Pfizer.  During his time at Takeda, Dr. O’Leary was a global project team leader for a late stage asset directing global strategy and regulatory approvals.  At ImmunoGen, he was the CMO and was responsible for guiding the strategic direction and execution of all clinical programs, including antibody-drug conjugates.  Prior to joining the biopharmaceutical industry, Dr. O’Leary was a medical reviewer with the U.S. Food and Drug Administration.  Before that, he was a practicing oncologist in New York. Dr. O’Leary obtained his doctor of medicine degree from the State University of New York, Health Science Center at Brooklyn and completed a fellowship in oncology/hematology at New York University Medical Center.

“I was eager to join the Fusion team because I believe we have an exciting opportunity to leverage novel science supported by robust manufacturing and supply chain capabilities to usher in a new therapeutic approach delivering precision cancer therapies to patients,” said Dr. O’Leary. “Beginning with FPI-1434, which is currently in Phase 1 development, I look forward to growing and optimizing our clinical programs and guiding our short and long term development strategies.”

Ends.

For further information, please contact Vicky La Touche-Price at Seroba on +35316334028.

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers.  Using its proprietary Fast-Clear™ Linker technology platform, the company attaches alpha particle emitting isotopes to targeting molecules to create novel, next-generation radiopharmaceuticals for the treatment of cancer.  In preclinical studies, the company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact to healthy tissue.  Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial.  The company completed an oversubscribed $125M Series B financing that will be used to advance FPI-1434 and initiate preclinical and clinical development on multiple new product candidates.

To leverage its proprietary platform further, Fusion is actively evaluating opportunities to in-license targeting molecules and form strategic partnerships to expand its pipeline of cancer therapies. For more information, please visit www.fusionpharma.com

Recent Articles

Quanta News

John S. Lipman Appointed as Quanta’s President, North America.

Alcester, Warwickshire, UK.  24 November 2020.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology […]

Read More
Home V2

Storm Therapeutics and Evotec Leverage Indigo Platform to Progress Oncology Project.

Storm’s First-in-Class clinical candidate against an RNA Methyltransferase for use in Cancer was identifed with support from Evotec’s Drug Discovery […]

Read More
Pq Bypass

PQ Bypass Releases Positive 24-Month Data from the DETOUR1 Clinical Trial.

MILPITAS, Calif.  November 12, 2020.  Seroba’s portfolio company, PQ Bypass, Inc, a medical device pioneer bringing new advancements to the […]

Read More
Heidi Zac Image

Heidi Zak, CEO of ThirdLove, joins INNOVO® in advisory role.

BOSTON, Nov. 10, 2020 Seroba’s portfolio company, Atlantic Therapeutics, has announced that Heidi Zak, co-founder and CEO of ThirdLove will […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top